Maxim Group launched coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $3 price target. The stock closed at 57 cents on Jan. 4.Read More
Leerink launched coverage of Synlogic (NASDAQ:SYBX) with an “outperform” rating and $25 price target. The stock closed at $18.73 on Sept. 18.Read More
H.C. Wainwright initiated coverage of OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) with a “buy” rating and a 12-month price target of €12.00. The stock closed at €6.25 on March 6.Read More
Leerink Partners launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with an “outperform” rating and $17 price target in 12 months. The stock closed at $12.08 on Friday.
Protagonist is aiming to become the standard of care therapy for moderate-to- severe irritable bowel disease (IBD) patients, a large and growing market opportunity.Read More
H.C. Wainwright has initiated coverage of Seres Therapeutics (NASDAQ:MCRB) with a “buy” rating and $55 price target. The stock closed at $24.88 on Friday.
Seres is developing restorative microbial treatments that aim to improve on the clinical success of fecal microbiota transplantation (FMT), an infusion of donor fecal matter into the colon, as a viable therapeutic modality, while improving safety and removing the “ick factor” from the process.Read More